期刊文献+

急性早幼粒细胞白血病170例长期生存分析 被引量:18

Long-Term Survival Analysis in 170 Cases of Acute Promyelocytic Leukemia
暂未订购
导出
摘要 本研究探讨影响急性早幼粒细胞白血病(APL)患者长期生存的预后因素。在回顾性分析了1990年1月至2004年12月本院170例APL患者的临床资料后,应用Log-Rank检验和Cox回归模型对170例患者的性别、年龄、初诊时白细胞(WBC)计数、血清乳酸脱氢酶水平、诱导缓解方案、获得缓解时间、缓解后治疗方案、PML/RARα阳性率进行单因素和多因素综合分析。结果表明:170例患者中位随访36个月(6-185个月),5年预计总体生存率(OS)为(80.9±4.0)%,5年预计无复发生存率(RFS)为(71.0±4.0)%。23例患者于中位缓解后15个月(6-70个月)复发。单因素分析显示,初诊时WBC计数、诱导缓解方案、获得缓解时间、缓解后治疗方案、PML/RARα阳性率均为影响APL患者长期生存的主要因素;多因素分析显示,缓解后治疗方案是影响APL患者长期生存的重要的独立因素。结论:在APL患者获得完全缓解后,应用化疗+维甲酸+砷剂的缓解后治疗方案将显著延长患者的生存时间。 This study was aimed to investigate various factors influencing long-term survival in patients with acute promyelocytic leukemia. A single institutional retrospective study with long-term follow-up was perfomed to better define the prognostic factors and a rationale for the use of ATRA, chemotherapy, and As2O3 in the treatment of newly diagnosed APL patients. Newly diagnosed patients with APL entering complete remission (CR) were followed up for 6 to 185 months (n=170) from January 1990 to December 2004. Univariate and multivariate analysis of 8 potential factors influencing survival and prognosis were carried out with Log-Rank and Cox regression method, including sex, age, initial WBC count, the level of lactic hydrogenase (LDH), first induction regimen, time from induction therapy to CR, post-remission therapy, negative or positive rate of PML-RAR alpha and follow-up of reverse transcdption-polymerase chain reaction (RT-PCR). The results showed that the estimated 5-year overall survival (OS) and relapse-free survival (RFS) were 80.9% ±4.0% and 71.0% ±4.0% respectively. The 23 patients relapsed at the median time of 15 months (6-70)after CR. Univariate analysis revealed that initial WBC count, first induction regimen, time from induction therapy to CR, type of post-remission therapy and persistent negative RT-PCR in remission were important prognostic factors for long-term survival. Multivariate study demonstrated that only type of post-remission therapy was associated with RFS and OS. It is concluded that the post-remission treatment combining ATRA, As2O3 and chemotherapy would significantly improve the long-term survival of APL patients entering CR1.
机构地区 中国医学科学院
出处 《中国实验血液学杂志》 CAS CSCD 2006年第3期437-441,共5页 Journal of Experimental Hematology
关键词 急性早幼粒细胞白血病 长期生存 预后因素 Acute promyelocytic leukemia long-term survival prognostic factors
  • 相关文献

参考文献13

  • 1Tallman MS,Anderson JW,Schiffer CA,et al.All-trans retinoic acid in acute promyelocytic leukemia.New Engl J Me d,1997;337:1021-1028
  • 2Tallman MS,Anderson JW,Schiffer CA,et al.All-trans retinoic acid in acute promyelocytic leukemia:long-term outcome and prognostic factor analysis from the North American Intergroup protocol.Blood,2002; 100:4298 -4302
  • 3张鹏,王树叶,胡龙虎,邱凤芹,杨惠芬,肖彧君,李晓霞,韩雪英,周晋,刘澎.三氧化二砷治疗急性早幼粒细胞白血病七年总结——附242例分析[J].中华血液学杂志,2000,21(2):67-70. 被引量:320
  • 4Asou N,Adachi K,Tamura J,et al.Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with alltrans retinoic acid and chemotherapy.J Clin Oncol,1998; 16:78-85
  • 5Burnett AK,Grimwade D,Solomon E,et al.Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid:results of the randomized MRC trial.Blood,1999; 93:4131-4143
  • 6Ohno R,Asou N,Kanamaru A,et al.The JALSG APL92 study for newly diagnosed acute promyelocytic leukemia (APL):analysis of prognostic factors to increase cure rate in the next study.Blood,1999; 94:2262a
  • 7Sanz MA,Martin G,Rayon C,et al.A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia.PETHEMA Group.Blood,1999; 94:3015-3021
  • 8Fenaux P,Chevret S,Guerci A,et al.Long-term follow-up confirms the benefits of all-trans retinoic acid in acute promyelocytic leukemia.European APL Group.Leukemia,2000; 14:1371-1377
  • 9Hu J,Shen ZX,Sun GL,et al.Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid,chemotherapy,and As2O3:an experience of 120 patients at a single institution.Int J Hematol,1999; 70:248 -260
  • 10李栋梁,宣宝和,张静.急性白血病血清乳酸脱氢酶测定及其预后意义的研究[J].中国医师杂志,1999,1(3):9-10. 被引量:19

二级参考文献8

  • 1房世荣 郭静琴 等.白血病患者血清乳酸脱氢酶及其同功酶的研究[J].中华血液学杂志,1993,4(3):152-152.
  • 2高效曾 杨惠蓉 等.尿及血清乳酸脱氢酶活力对小儿急性白血病的意义[J].陕西医学杂志,1993,22(10):601-601.
  • 3贝政平,3200个内科疾病诊断标准,1998年
  • 4张之南,血液病诊断及疗效标准(第2版),1998年
  • 5王世俊,金属中毒(第2版),1988年
  • 6Gonzalez M, Barragan E, Bolufer P, et al. Pretreatment characteristics and clinical outcome of acute promyelocytic leukemia patients according to the PML/RARet isoforms: a study of the pethema Group.Br J Haematol,2001 , 114:99 - 103.
  • 7Gupta V. Prognostic significance of PML/RARα isoforms in adult patients with acute promyelocytic leukemia treated with all trans retipnoic acid ( ATRA ) and chemotherapy. ASH, 2002 , 11 ( poster 1266).
  • 8Meloni G, Diverio D, Vignetti M, et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission :prognostic relevance of pretransplant minimal residual disease assessment by reverse - transcription polymerase chain reaction of the PML/RAR fusion gene. Blood, 1997 ,90 : 1321 - 1325.

共引文献343

同被引文献145

引证文献18

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部